Next Article in Journal
Environmental and Host Characteristics Shape the Gut Microbiota of the Sand Field Cricket, Gryllus firmus
Next Article in Special Issue
Moderate Phosphorus Addition to Field-Grown Bananas Enhanced Soil Microbial Enzyme Activities but Had Negligible Impacts on Bacterial, Fungal, and Nematode Diversity
Previous Article in Journal
Incorporation of Cyanobacteria and Microalgae in Yogurt: Formulation Challenges and Nutritional, Rheological, Sensory, and Functional Implications
Previous Article in Special Issue
Molecular Typing of Somatic Coliphage Groups and Their Occurrence and Survival in Sewage
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Salmonella: Role in Internal and External Environments and Potential as a Therapeutic Tool

by
Patrick J. Naughton
*,
Violetta R. Naughton
and
James S. G. Dooley
Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine BT52 1SA, UK
*
Author to whom correspondence should be addressed.
Appl. Microbiol. 2024, 4(4), 1515-1533; https://doi.org/10.3390/applmicrobiol4040104
Submission received: 28 August 2024 / Revised: 31 October 2024 / Accepted: 1 November 2024 / Published: 8 November 2024

Abstract

:
Salmonella has had a long and intimate relationship with humans and continues to raise concerns for human health, but this close bond also provides opportunities for new therapeutics and treatments. Although Salmonella enterica serovar Typhi is the principal organism that comes to mind in terms of death and morbidity, it is the non-typhoidal Salmonellae that have the most health and economic implications. The developed world has had a challenging relationship with Salmonella, particularly in the UK and the EC/EU, experiencing significant Salmonella outbreaks in the 1980s and 1990s. As a consequence, the research focus was on understanding the nature of infection in food animals and on developing ways and means of controlling zoonotic infections. This led to the development of numerous model systems for the study of Salmonella both in vitro and in vivo. The introduction of vaccination has all but eliminated Salmonella in eggs and reduced perceived risk held by the general public. At the same time as Salmonella in eggs was being brought under control in the UK and EU, the danger posed by antibiotic resistance was beginning to emerge. In the past, with the efficacy of antibiotics against Gram-negative bacteria being unchallenged, there was limited focus on the threat posed by antibiotic resistance in non-typhoidal Salmonella. However, the identification of Salmonella as the first ‘multidrug-resistant’ organism, the presence of invasive non-typhoidal Salmonella in North Africa and the emergence of monophasic Salmonella enterica serovar Typhimurium across Europe, Asia and the Americas have prompted renewed interest in Salmonella research, particularly in the context of non-infectious disease, biofilm studies and antibiotic resistance. At the same time, research has continued to develop ways of taking advantage of what Salmonella offers in the way of pathogenic factors and the therapeutic and treatment applications in areas such as vaccine development, cancer therapeutics and drug delivery and the role of Salmonella in non-infectious diseases supported by developments in molecular and genomic methods.

Graphical Abstract

1. Introduction

The focus of Salmonella research has ebbed and flowed in the last three decades. The challenge of Salmonella zoonosis in the 1990s, required better isolation, detection and identification methods for non-typhoidal Salmonella (NTS). The advent and development of molecular methods have meant the successful replacement of the gold standard pulse-field electrophoresis (PGGE) method with the adoption of whole-genome systems including multilocus sequence typing (MLST) [1,2]. Whole-genome sequencing (WGS) can be used to detect and control Salmonella [3] in a number of ways, including the following: serotyping [4] (the SeqSero web-based tool can predict Salmonella serotypes using WGS data [5]); AMR (WGS is a rapid and accurate tool for AMR surveillance [6]); subtyping (WGS can be used with single-nucleotide polymorphism (SNP) and multilocus sequence type (MLST) subtyping methods to identify genetically related genomes); outbreak surveillance (WGS can be used in combination with real-time epidemiological investigation to detect and investigate outbreaks, e.g., SIEGA) [7,8]. The work on Salmonella enterica serovar Typhi has been particularly important both in terms of understanding the genetic separation of NTS (reviewed in detail [9]) and the potential of S. Typhi as a vaccine tool. The observation that typhoidal and NTS infections induce such different clinical presentations and immune responses in humans may be attributed to a degree of metabolic and virulence gene degradation that exists in the genomes of typhoidal serovars, perhaps explaining the restricted host tropism of these pathogens [10]. It has been suggested that NTS serovars have evolved to flourish in the inflamed gut environment and use inflammation to outcompete the normal microbiota [11]. It has been proposed that typhoidal strains may have lost this ability and so do not induce inflammation but act systemically instead. In addition, the move by the statutory agencies in the UK [3] and elsewhere towards whole-genome sequencing (WGS) analysis with both SNP- and allelic-based methods for the detection and identification of Salmonella means the potential is now there for very detailed and precise information that previous conventional methods were unable to provide. The complications of antimicrobial resistance (AMR) have also resulted in fluoroquinolone-resistant NTS being included in an unenviable club of bacteria, the WHO’s list of antibiotic-resistant high-priority pathogens [12], and considered a research priority as part of the WHO global research agenda [13]. This review seeks to bring together elements of Salmonella research that have tended to be looked at in isolation in the past. There is no doubt that a more holistic approach to Salmonella science is required. The One-Health initiative adopted in the face of the unrelenting increase in global antimicrobial resistance is a possible approach for integrating some of the currently more disparate topics. The objectives of this review are as follows: to highlight the importance of newly emerging variants and serovars; to detail the impact of Salmonella biofilms in the internal and external environments; to focus attention on the potential of Salmonella as an anti-viral and anti-cancer tool; to highlight Salmonella as a platform for vaccines and in particular anti-cancer vaccines.
This review is not exhaustive; it focusses on aspects of Salmonella and applied research that impact discrete areas of health and the environment. This review considers the current state of Salmonella research in terms of the fight against the disease and the potential therapeutic applications of Salmonella (Figure 1).

2. Emerging Salmonella Variants

Focus on WGS tools has been spurred on by newly emerging variants including the occurrence of invasive non-typhoidal Salmonellosis (iNTS). The presence of iNTS was first recognised in West Africa associated with malaria and East Africa with malnourishment; interest in iNTS has increased because of the levels of multidrug resistance associated with these strains, and the implications for the very young, old, malnourished and immunocompromised are significant. Whereas their function as a reservoir of disease and human transmission is unclear, those strains causing disease are the most notable because of their invasive phenotype accompanied by genome degradation. A review by Reddy and co-workers [11] found NTS to be responsible for 29.1% of all bloodstream infections, and NTS bacteraemia is an important cause of morbidity and death in Africa. Van Puyvelde and colleagues [14], investigating invasive S. Typhimurium (iNTS) in sub-Saharan Africa, found specific risk factors for iNTS infection (malnutrition, HIV and malaria coinfections) to be significant in the human population. Water, sanitation and hygiene, nutrition and control of malaria and HIV are all confounders in endemic regions. Unfortunately, the data on NTS bacteraemia in Africa remain limited, so it has been difficult to estimate the true burden. Nonetheless, these infections are a significant obstacle to economic progress in developing countries, hence the need for efficacious and cost-efficient vaccines for Africa. The emergence of the iNTS variant has been closely followed by monophasic S. Typhimurium (for a detailed review, see [15]. It lacks one or more flagellar assemblies [16], i.e., the fljB-encoded second-phase H antigen. Moreover, the rise in monophasic cases has been associated with disease in humans, particularly the young and the elderly, compounded by the multidrug resistance associated with this variant.
The monophasic variant of Salmonella enterica serovar Typhimurium (mST), namely S. Typhimurium (4, [5], 12:i:-), was initially associated with pork zoonosis in Europe [17] and, though rarely reported before the 2000s, has now become the third most common serovar in the EU and UK [18]. It is placed in the top five serovars in human infections according to the most recent EFSA and ECDC report [19] and was most recently associated with a pan-European outbreak associated with chocolate intake in children [20]. ASSuT, known as the ‘European Clone’, is the predominant MDR pattern found in mST in China [21], with a Spanish clone exhibiting a unique ACSuGSTTM profile. Indeed, mST and Salmonella enterica serovar Infantis are amongst the five serovars most associated with human cases of Salmonellosis in the EU in 2021 [22]. A systematic review of studies published in China found a high multidrug resistance rate (86%) associated with the detection prevalence of mST, higher in Southern China compared to Spain and the USA but lower than in Italy [23,24,25,26]. An analysis of isolates sequenced (2015–2018) in the USA found that 63% of human cases were associated with pork consumption/contact with swine and had the ASSuT profile [27]. It is thought that the level of multidrug resistance in mST may have contributed to the rapid spread of the serovar.
Amongst the Salmonella serovars in circulation, Salmonella entericia serovar Rissen (S. Rissen) [28,29] is now frequently reported worldwide and has a significant association with the intensive pig industry. The most recent ECDC report [30] places S. Rissen in the top 20 of the most frequent Salmonella serovars associated with human Salmonellosis. S. Rissen is the predominant serotype associated with swine production in Thailand [31]. Elbediwi and colleagues [32] reported that the majority of S. Rissen isolates from across China were derived from humans (63.4%; 749/1182). In China, pork continues to dominate the diet, and significant cases of S. Rissen have been reported [32]. Wang and colleagues [33] have confirmed earlier work dividing S. Rissen into two clusters, Clusters A and B. Wang and co-workers further subdivided Cluster B into Clusters B-1 and B-2, with B-2 showing additional profiles of quinolone (qnrS1), chloramphenicol (cmlA1) and tetracycline (tet(M)) resistance. The authors suggest that this continuing divergence demonstrates the ability of S. Rissen to continually evolve through pork production based on its evolving MDR profile. More recently, significantly higher resistance rates have been identified in strains isolated from humans compared to non-human sources [34], with higher frequencies of multidrug resistance and probable clonal dissemination in this serovar. In common with these studies, work on Portuguese isolates [35] has found a low degree of genetic diversity but a high degree of genetic relatedness in this serovar related to pork production. Their analysis identified the presence of two major clusters composed of MDR isolates, with the majority being resistant to at least five antibiotics. This may go some way towards explaining the continuing spread of this serovar.
The emergence of new variants is not restricted to bacterial competition or antibiotic pressure; several workers have already identified a number of the seasonal influences on Salmonella outbreaks [36,37,38], both in the environment and the inevitable clinical cases. There is also, with climate change [39], the potential for increases in susceptibility to plant fungal infections making vegetable crops more sensitive to Salmonella carriage [40,41]. Temperature fluctuations [42] and extreme weather events can impact Salmonella transmission in a number of ways, including faster replication (for every 5 °C rise, there can be a 5–10% increase in infections), contaminated crops (floodwaters can carry Salmonella bacteria from sewage, animal waste and soil into crops) and contaminated water (floodwaters can contaminate drinking water and also recreational waters (including seawater)), all with significant implications for human health (reviewed in detail by [22,43]). Without a doubt, it is low- to middle-income countries that will be the least well prepared to deal with the impact of climate-induced increases in Salmonella outbreaks [44]. There are also agricultural developments in response to sustainability, e.g., the increased utilisation of animal manures and soil supplementation [45,46]. These inputs may have implications for an increase in pathogenic organisms, including Salmonella, in fruits, grains and vegetables, and a subsequent increase in clinical cases.

3. Salmonella in the External Environment

In the natural environment as well as the host, biofilms are important for microbial survival. The main challenges associated with Salmonella biofilm formation in the clinical and food environments are detection and removal. S. Infantis causes particular issues in the poultry industry [47]. Despite being an intestinal pathogen, S. Infantis can readily persist outside the organism’s host by forming biofilm as an important survival adaptation mechanism. Cwiek and colleagues [48], investigating Salmonella enterica serovar Enteritidis, found that those isolated from poultry exhibited better biofilm growth than strains isolated from humans. Furthermore, studies have shown that biofilm formation provides tolerance to various stressors (temperature, pH, disinfection, antibiotics, etc.) encountered in both host and non-host environments (reviewed in detail by [49]). The expression of curli and cellulose, well-recognised adhesins for both biotic and abiotic surfaces, is strongly dependent on temperature, leading to an increase in persistence [50]. Antibiotic treatment is only recommended in vulnerable patients, such as the young, the elderly and patients with weakened immunity with biofilms identified in key areas of pathogenicity of disease [51]. Typhoid fever is an acute food-borne illness, predominantly caused by Salmonella enterica serovar Typhi, that is often characterised by high fever, weakness, headache, abdominal pain and constipation. If it is untreated, serious complications may arise, including intestinal bleeding, bowel perforation, septicaemia, meningitis and death.
S. Typhimurium has the ability to form biofilms on the many materials we associate with the built environment, including products in everyday use such as glass, stainless steel and plastic [52]. This has implications both for the food and clinical environments. Given its ability to colonise these everyday surfaces, it follows that S. Typhimurium biofilm can survive on food contact surfaces for significant periods with the added complication of it being difficult to remove [53]. Along with contact surfaces, Salmonella have the ability to form biofilms on food under favourable conditions [54,55,56]. The formation of Salmonella biofilm increases the risk of microbial contamination in the food chain and consequently impacts clinical health; it is a complex process regulated by different genes whose contributions are just beginning to be elucidated [57]. The genes adrA, csgD, fljB and flhD and sRNAs (ArcZ, CsrB and SroC) may play significant roles in S. Typhimurium biofilm formation [58,59,60]. For instance, adrA regulates cellulose synthesis through c-di-GMP [61]; CsgD regulates the expression of matrix compounds [62,63,64]. Cell motility is important in the initial attachment to the contact surfaces and hence biofilm production [65], with fljB and flhD genes being critical for flagellar regulation. Simulated gastrointestinal conditions (pH, agitation, enzymatic activity) have an effect on biofilm formation [66], with biofilm formation in mST thought to be beneficial in its dissemination. Biofilm formation enables infection and persistence in the environment [61,67], with a range of genes having already been identified as being involved (Table 1). Although traditionally associated with poultry, meat and dairy products, there has been a renewed interest in Salmonella biofilms because of outbreaks associated with low-moisture conditions [68] and ready-to-eat products which now dominate Western supermarkets [69,70]. Salmonella have been shown to survive for long periods of time in low-moisture foods [71]; hence, it is important that we understand the genes and regulatory processes involved and be in a position in the future to introduce appropriate control measures.

4. Salmonella Biofilm in Body Systems (Internal)

Whereas the external environment sees NTS in the ascendancy, the internal human environment is more impacted by S. Typhi (reviewed in detail [49]). It was initially unclear whether biofilm could form in vivo due to a lack of evidence of csgD expression in NTS isolates tested at temperatures ≥37 °C [62]. In the case of S. Typhi, we are more familiar with the acute disease (typhoid fever). However, it is now clear that Salmonella produces Extracellular Polymeric Substances (EPSs) in vivo and that there is an association with chronic infections [81], and environmental signals other than temperature may be able to counteract its effects on csg expression [82]. Notwithstanding, there is evidence of Salmonella biofilm formation in various in vivo systems, including chronic gallbladder carriage of the human-specific S. Typhi [83].
Gallstones provide a suitable surface for the attachment of S. Typhi biofilms [84,85] and the development of similar disorders. Flagella may play a role in the initial attachment of S. Typhi to gallstone cholesterol surfaces mediated by FliC [86]. S. Typhi can also secure itself to the gallbladder epithelium [85,87,88]. Biofilm may provide protection to Salmonella from bile, bile salts and antibiotic therapy in the gallbladder environment, facilitating long-term survival and further transmission [81,89]. During chronic infections, the immune system interacts with Salmonella biofilms in a number of ways, including the following: inhibiting apoptosis; inducing an inappropriate or skewed immune response [90]; tolerance to innate immunity; host cell damage and establishing itself in M2 macrophages [49,81] (see [91] for a detailed review on chronic infections). Recently, [92], investigating starvation, biofilm production in S. Typhi and adherence, identified a central role for rpoS in regulating this process.
Chronic gallstone biofilm carriers are the only known reservoir of S. Typhi, and individuals have been shown to continue shedding for 12 months or more [83]. There is a strong correlation between the carriage of chronic S. Typhi and gallstones, with the latter considered a major risk factor for gallbladder cancer (GBC), [93]. While GBC is a (relatively) rare malignancy in Western countries, its incidence is higher in countries with endemic S. Typhi, with typhoid toxin (CDT) having a possible role in long-term infection. CDT induces DNA double-stranded breaks and the activation of the MAPK and AKT pathways, leading to the transformation of pre-transformed cells [93,94]. The association between S. Typhi infection and/or chronic carriage and cancer has become well recognised along with the role of Salmonella in other chronic diseases [95].
There is limited evidence in vitro of NTS infection being accompanied by biofilm formation [96,97,98,99,100], and that evidence is restricted to adherence to human and chicken epithelial cells. Work with HT-29 cells and S. Typhimurium biofilm-forming strains suggested a reduction in virulence. In contrast, Salmonella enterica serovar Enteritidis biofilm formation on Hep-2 and Caco-2 cells was correlated with virulence, although the comparison was of different serovars in different cell lines [96,99]. S. Typhimurium biofilms may also be involved in the formation of extracellular aggregates in vivo. In the Caenorhabditis elegans gut model, CsgD-dependent formation of aggregates was associated with bacterial persistence and host survival, possibly linked to transmission of similar populations in the mouse large intestine [101,102,103]. However, evidence of NTS infections in the human intestine involving biofilms is limited [10,104]. Salmonella curli are thought to be a major mechanism in biofilm formation [105,106,107], and the production of curli amyloids has been shown in the gastrointestinal (GI) tract of orally infected mice. So, biofilm genes may be expressed during a human infection, but the determinant genes required to establish biofilm are still unclear [106,107,108].
The ability of Salmonella to form biofilm in vivo likely leads to bone disease in addition to diseases of organs and soft tissue. Though rare, Salmonella osteomyelitis does occur [109]. In Africa, it is commonly associated with sickle cell anaemia including spleen damage, defects in complement activation, genetic factors, deficiencies in micronutrients and the presence of infarcted or necrotic bone (for a detailed systematic review, see [110]). In children with haemoglobinopathies, it is a significant cause of morbidity and death [110]. In these situations, gut-borne bacteria may enter the blood stream, and blood-borne bacteria may enter damaged bone. Failure and near-failure of the liver and spleen may also reduce the clearance of blood-borne bacteria, and this may be particularly damaging in the young [111,112]. Immunocompromised adults may have Salmonella-associated osteomyelitis despite the common risk factors for infection being absent [113,114].
Much of the evidence identifying biofilm formation with persistence in NTS is from zoonotic work [115]. However, there is increasing evidence of similar findings in humans [49,116]. It appears that the ability to form a biofilm is a conserved trait found in numerous serovars of S. enterica, with biofilm formation allowing Salmonella to persistently colonise sites both inside and outside of the animal host, which in combination with AMR (Figure 2A) is the ultimate enhancement of both bacterial survival and transmission.

5. Salmonella Combatting Non-Infectious Diseases Including Cancer

S. Typhimurium is suitable for oral administration [117] and can induce mucosal and systemic immune responses [118,119]. The early Salmonella aroA, aroC or aroD mutations prevented the development of infection but persisted enough for an immune response. Genetically modified recombinant attenuated Salmonella vaccine (RASV) strains can display a hyperinvasive phenotype to maximise Salmonella host entry and allow for host cell internalisation. This has resulted in a strain capable of evading apoptosis, prompting DNA to more efficiently enter the target cell [120], and the manipulation of lipid A (as an immunogen) has resulted in an improved vaccine carrier [121]. The potential of Salmonella as/in vaccines against non-infectious diseases is of particular interest [122,123], though there are few examples that have progressed even to animal trials; e.g., Hauer and colleagues [124] used an S. Typhimurium encoding VEGFR2 to reduce atherosclerosis in mice.
The suggestion that bacterial systems could be used to treat cancers is not new. In the late 1800s, Coley improved patient outcomes using a Streptococcus pyogenes injected into cancers (cited in [125]). Salmonella was not originally included in the scenario of the Coley vaccines, but it was later recognised that Salmonella not only could be a potential therapy [126] in the fight against cancer but also may be a risk factor in the development of cancer/cancer risk, and S. Typhi itself may have a role in some cancers [127]. Duijster and colleagues [128] identified 10 bacteria including NTS and S. Typhi associated with gastrointestinal cancers. Notwithstanding the clear linkages between S. Typhi and GBC, there is evidence of Salmonella-mediated anti-tumour therapy promoting significant tumour suppression and prolonged survival in many studies [129]. Salmonella’s potential as a therapeutic tool (Figure 2B) has been reviewed in detail [130], and work in experimental models [131] has shown that repeated exposure to NTS increases the risk of colon cancer. Shanker and Sun [132], in their review of Salmonella as an environmental risk factor, identified repetitive NTS infections as significant in the proliferation of transformed cells in tissue cultures.
Salmonella bacteria have been studied as a potential treatment for cancer in a process called bacterial-mediated cancer therapy (BMCT), [133]. These therapies include tumour targeting, drug delivery, combination therapies, immune response stimulation, genetic modification and the ability to utilise a hypoxic environment [134]. The potential benefits of Salmonella-mediated therapy include stronger tumour suppression, improved side effects, inhibition of tumour growth and prolonged survival (in mice) [135]. To combat cancer, a number of approaches have been suggested [136,137,138], among which the anti-tumour effects of S. Typhimurium LT2 CRC2631 are probably the most studied [139]. Other Salmonella serovars have been investigated as models, e.g., Salmonella entericia serovar Choleraesuis [140,141]; however, VNP20009 [142] and A1-R1 [143], e.g., the prevention of tumour angiogenesis in a mouse model by VNP20009 along with endostatin [144], remain the most prominent in the literature (see Table 2). The oncolytic capacity of Salmonella and its ability to reduce tumour growth are clearly an advantage, but these tumours can grow back following treatment; therefore, attention has been given to direct killing by immune molecules [145]. The outer membrane vesicles (OMVs) of Salmonella (reviewed in detail [146]) may have potential over attenuated strains in terms of safety, and their immunogens can activate the immune system. The intrinsic mechanisms of Salmonella crucial in combating cancer are still being elucidated (reviewed in detail [147]).
The ability to target tumour regions is important [152,153]. The natural toxicity of S. Typhimurium towards tumours and its ability to cope in an anoxic environment coupled with cytokine involvement make it the ideal tool [154,155]. Salmonella, protected as it is by the immune system [156,157,158], may provide efficacy in terms of an adjuvant effect or in tumour colonisation [159]. The balance of safety and therapeutic efficacy is crucial and, as mentioned previously, has resulted in two prominent Salmonella vector strains, VNP20009 and A1-R [160]. Over-manipulation of VNP20009 has resulted in it being less effective in some instances [141], with the loss of anti-tumour properties, whereas the variant A1-R has shown potential in murine tumours and patient-derived orthotropic xenografts [143,144]. In contrast, SF200, which contains mutations affecting LPS and flagella synthesis has been shown to increase immune stimulation [143,144]. However, despite these advances, challenges remain in the selection of an appropriate model coupled with the approaches to developing Salmonella as a tool against cancer. Despite the number of high-quality publications in the area [130], evidence of efficacy in humans is limited to a few clinical trials where there has been some success (for an extensive review, see [161]), including an IL-2-expressing, attenuated S. Typhimurium in the unresectable hepatic spread of a solid tumour (https://www.clinicaltrials.gov/study/NCT01099631, [162], accessed on 28 October 2024).
Salmonella shows promise as a live attenuated agent, with workers investigating a range of effectors including interleukins and cytokines. The anti-tumour effects of S. Typhimurium expressing proinflammatory cytokines and monocytes have also been identified in melanoma-bearing mice. More recently, it has been shown that tumour antigen coating promoted antigen-specific CD8+ T immunity with increased Type 1 interferon anti-tumour activity [163], indicating that Salmonella does harness immunological processes, albeit indirectly. Zha and colleagues [164] found that AvrA suppressed intestinal inflammation and inhibited the secretion of cytokines IL-12, IFN-γ and TNF-α. AvrA expression in Salmonella enhanced its invasiveness. Liver abscesses and Salmonella translocation to the gallbladder were observed. Further studies have emphasised the importance of AvrA in intestinal inflammation, bacterial translocation and chronic infection associated with colon cancer in vivo. That being said, there are also some disadvantages to the BMCT platform in cancer therapy, including safety issues. Salmonella-mediated cancer therapy (SMCT) has faced specific problems, with most phase I clinical trials having unsatisfactory outcomes. For a successful clinical outcome, the intrinsic and extrinsic factors associated with tumours [130] and the ability to clear Salmonella from the area around tumours are crucial to the success of SMCT in clinical applications. Moreover, efforts to balance attenuation may increase the risk of septic shock, and pre-exposure to these pathogens in the environment may have induced immunity against these pathogens, so vector-specific immunity may ultimately interfere with actual vaccine delivery.

5.1. Drug with a Pro-Drug Activating Enzyme

This innovative approach entails a systemic pro-drug being converted to a cytotoxic drug and resulting in a localised anti-tumour effect; for instance, CD-20-targeting antibodies [165] and an engineered VNP20009 [166]. S. Typhimurium expressing HSVtk showed GCV-mediated, dose-dependent suppression of tumour growth in mice bearing B16F10 melanoma [167,168]. Using S. Infantis as an HSVtk-expression vector has resulted in similar anti-tumour activity in a rat model of bladder cancer [169], with Zhou and co-workers [170] showing the suppression of metastasis is a range of tumour models.

5.2. Induction of Cell Death

S. Typhimurium expressing FasL can initiate an apoptotic signal in Fas-sensitive cells [171,172] and has been shown to inhibit tumour growth in breast and colon carcinoma models [173], and recombinant VPN20009 can extend survival in tumour-bearing mice by inducing more apoptosis [174]. Salmonella incorporating hypoxic-inducible NirB and radiation-inducible RecA reduced tumour growth and prolonged survival [175], with Chen and co-workers [176] showing that triptolide (TPL) could lead to enhanced apoptosis in B16F10 cells in vitro. Attenuated S. Typhimurium carrying a cytotoxic protein (HlyE) has been shown to increase tumour necrosis and growth retardation [177]. Moreover, Guan and co-workers [178] showed that using an apoptin-expressing S. Typhimurium extended tumour growth retardation and reduced micro-vessel density systemically. More recently, SPI-1 and SPI-2 have been shown to affect host inflammatory pathways to induce cytotoxicity and cellular apoptosis in RAW264.7 macrophages [179].

5.3. Post-Translational Gene Silencing

Salmonella may be advantageous in overcoming some of the difficulties involved in gene silencing in eukaryotic cells. Small interfering RNA (siRNA) breaks down quickly in the extracellular environment [180,181], restricting entry to eukaryotic cells. An attenuated S. Typhi for multidrug-resistance gene (MDR1) siRNA showed the potential of this approach [182], with Xiang and co-workers [181] showing the transfer of RNAi effector molecules from bacterial vectors to mammals in vivo. Furthermore, work using S. Typhimurium against tumour transcription factor STAT3 showed that combined therapy performed better than the vector alone [183], with further work [184] illustrating the silencing of targeted gene VNP (PhoP/Q-) with the release of an shRNA-expressing plasmid into the cytoplasm of host cells.
Delayed tumour growth and prolonged survival in a murine melanoma model were observed in the development of an orally administered S. Typhimurium incorporating a short-hairpin RNA targeting bcl-2. S. Typhimurium transformed with an shRNA plasmid was effective against indoleamine 2,3-dioxygenase 1 (IDO) in tumour-bearing mice. Silencing host IDO expression [185] resulted in intra-tumoral cell death with significant tumour infiltration by polymorphonuclear neutrophils. This silencing also enhanced S. Typhimurium colonisation, potentially mediating the immune response to S. Typhimurium. An S. Typhimurium VNP20009 targeting IDO [186] was shown to activate innate immunity and mitigate colorectal cancer growth. An S. Typhimurium strain delivering antisense RNA was also effective in silencing RCAS1 mRNA expressed in cancer cells and tumour tissues [187]. Hence, some promising RNAi-mediated anti-tumour therapeutic strategies have been developed, and further investigation will expand potential applications.

6. Salmonella as an Anti-Viral

The potential of bacteria-based therapies and Salmonella in particular as anti-virals gained renewed interest during and following the SARS-CoV-2 pandemic. Salmonella has some natural advantages over other therapy platforms in terms of its potential as an oral vaccine and the advantages that might afford in developing countries. Bacteria-based orally administered vaccines have attracted attention as a safer vaccine technology compared with vascular or intramuscular injection approaches (reviewed in detail [161]). Karpenko and colleagues [188] tested an orally administered S. Enteriditis vector (E23) harbouring genes encoding immune-dominant HIV antigens in mice, generating both humoral and T-cellular responses against HIV-1, and Chen and colleagues [189] showed that a plasmid carrying attenuated Salmonella could induce the production of HPV16-L1 antibodies and IL-2 and INF-y in mice serum. Furthermore, Yoon and colleagues [190] developed engineered spike proteins of SARS-CoV-2 which triggered SARS-CoV-2-specific antibody production and activated COVID-19-specific cellular immune responses. This orally administrated Salmonella BRD509 was shown to have reduced cytotoxic effects in vivo. Hence, these in vitro and in vivo data suggest that Salmonella strains may represent a valuable new delivery system for COVID-19 vaccines. Notwithstanding the potential benefits, it is also important to be mindful that Salmonella has been seen to interact with COVID-19 infections with an as yet uncharacterised role in long COVID-19 [191]

7. Future Developments

Combatting multidrug-resistant Salmonella in the context of an ever-dwindling number of effective antibiotics will be a focus of future work. Current work on therapeutic vaccines, particularly mRNA delivery, would appear to hold particular promise. Increasing the efficacy of current antibiotics [192,193] together with the development of prophylaxis or therapeutic vaccines to fight Salmonella infection will be paramount. There is the potential to develop therapeutic vaccines, particularly in terms of new and emerging variants [194], their zoonotic origin [195,196] and outbreaks [197]. A stumbling block is the lack of translation of the published research, so perhaps a consolidation of platforms would speed up the development of real-world outcomes. Vaccine development is one area where this consolidation of platforms and adoption of BMCT would be advantageous [133]. An increased understanding of biofilms, particularly in the external environment, could be key not only in the control of Salmonella but also in the spread of antibiotic resistance. There is no doubt that climate change will be the most challenging for society in the near to long term. One of the most significant challenges will be how research will address potential increases in newly emerging variants in the face of Salmonella fitness and antibiotic resistance in low- to middle-income countries in the Global South.

8. Conclusions

While researchers continue to push forward their ideas on the clear advantages of Salmonella as a worthwhile tool in the fight against both infectious and non-infectious diseases, the reality of disease-causing Salmonella coupled with the rise in multidrug resistance continues to confound them. Ultimately, a breakthrough application in targeted molecular tools will be required to take full advantage of this remarkable organism.

Author Contributions

Conceptualisation, P.J.N.; writing—original draft preparation, P.J.N.; writing—review and editing, P.J.N., V.R.N. and J.S.G.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created in the preparation of this manuscript.

Acknowledgments

We acknowledge the support provided by the School of Biomedical Sciences, Ulster University.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Banerji, S.; Simon, S.; Tille, A.; Fruth, A.; Flieger, A. Genome-Based Salmonella Serotyping as the New Gold Standard. Sci. Rep. 2020, 10, 4333. [Google Scholar] [CrossRef] [PubMed]
  2. Petrin, S.; Wijnands, L.; Benincà, E.; Mughini-Gras, L.; Delfgou-van Asch, E.H.M.; Villa, L.; Orsini, M.; Losasso, C.; Olsen, J.E.; Barco, L. Assessing Phenotypic Virulence of Salmonella Enterica across Serovars and Sources. Front. Microbiol. 2023, 14, 1184387. [Google Scholar] [CrossRef] [PubMed]
  3. Chattaway, M.A.; Dallman, T.J.; Larkin, L.; Nair, S.; McCormick, J.; Mikhail, A.; Hartman, H.; Godbole, G.; Powell, D.; Day, M.; et al. The Transformation of Reference Microbiology Methods and Surveillance for Salmonella with the Use of Whole Genome Sequencing in England and Wales. Front. Public Health 2019, 7, 317. [Google Scholar] [CrossRef] [PubMed]
  4. Ibrahim, G.M.; Morin, P.M. Salmonella Serotyping Using Whole Genome Sequencing. Front. Microbiol. 2018, 9, 2993. [Google Scholar] [CrossRef]
  5. Bao, D.; Chen, L.; Shen, W.; Xu, X.; Zhu, L.; Wang, Y.; Wu, Y.; He, X.; Zhu, F.; Li, H. Genomic epidemiology of ceftriaxone-resistant non-typhoidal Salmonella enterica strain in China. BMC Genom. 2024, 25, 974. [Google Scholar] [CrossRef]
  6. Davies, N.; Jørgensen, F.; Willis, C.; McLauchlin, J.; Chattaway, M.A. Whole genome sequencing reveals antimicrobial resistance determinants (AMR genes) of Salmonella enterica recovered from raw chicken and ready-to-eat leaves imported into England between 2014 and 2019. J. Appl. Microbiol. 2022, 133, 2569–2582. [Google Scholar] [CrossRef]
  7. Stevens, E.L.; Carleton, H.A.; Beal, J.; Tillman, G.E.; Lindsey, R.L.; Lauer, A.C.; Pightling, A.; Jarvis, K.G.; Ottesen, A.; Ramachandran, P.; et al. Use of Whole Genome Sequencing by the Federal Interagency Collaboration for Genomics for Food and Feed Safety in the United States. J. Food Prot. 2022, 85, 755–772. [Google Scholar] [CrossRef]
  8. Casimiro-Soriguer, C.S.; Pérez-Florido, J.; Robles, E.A.; Lara, M.; Aguado, A.; Rodríguez Iglesias, M.A.; Lepe, J.A.; García, F.; Pérez-Alegre, M.; Andújar, E.; et al. The integrated genomic surveillance system of Andalusia (SIEGA) provides a One Health regional resource connected with the clinic. Sci. Rep. 2024, 14, 19200. [Google Scholar] [CrossRef]
  9. Kariuki, S.; Revathi, G.; Kariuki, N.; Kiiru, J.; Mwituria, J.; Muyodi, J.; Githinji, J.W.; Kagendo, D.; Munyalo, A.; Hart, C.A. Invasive Multidrug-Resistant Non-Typhoidal Salmonella Infections in Africa: Zoonotic or Anthroponotic Transmission? J. Med. Microbiol. 2006, 55, 585–591. [Google Scholar] [CrossRef]
  10. Gal-Mor, O.; Boyle, E.C.; Grassl, G.A. Same Species, Different Diseases: How and Why Typhoidal and Non-Typhoidal Salmonella Enterica Serovars Differ. Front. Microbiol. 2014, 5, 391. [Google Scholar] [CrossRef]
  11. Thiennimitr, P.; Winter, S.E.; Bäumler, A.J. Salmonella, the host and its microbiota. Curr. Opin. Microbiol. 2012, 15, 108–114. [Google Scholar] [CrossRef] [PubMed]
  12. WHO Bacterial Priority Pathogens List, 2024: Bacteria Pathogens of Public Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance; World Health Organisation: Geneva, Switzerland, 2024.
  13. WHO Global Research Agenda for Antimicrobial Resistance in Human Health; World Health Organisation: Geneva, Switzerland, 2023.
  14. Van Puyvelde, S.; de Block, T.; Sridhar, S.; Bawn, M.; Kingsley, R.A.; Ingelbeen, B.; Beale, M.A.; Barbé, B.; Jeon, H.J.; Mbuyi-Kalonji, L.; et al. A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan Africa. Nat. Commun. 2023, 14, 6392. [Google Scholar] [CrossRef] [PubMed]
  15. Uche, I.V.; MacLennan, C.A.; Saul, A. A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Non-typhoidal Salmonella (INTS) Disease in Africa (1966 to 2014). PLoS. Negl. Trop Dis. 2017, 11, e0005118. [Google Scholar] [CrossRef] [PubMed]
  16. Feasey, N.A.; Dougan, G.; Kingsley, R.A.; Heyderman, R.S.; Gordon, M.A. Invasive Non-Typhoidal Salmonella Disease: An Emerging and Neglected Tropical Disease in Africa. Lancet 2012, 379, 2489–2499. [Google Scholar] [CrossRef]
  17. Kingsley, R.A.; Msefula, C.L.; Thomson, N.R.; Kariuki, S.; Holt, K.E.; Gordon, M.A.; Harris, D.; Clarke, L.; Whitehead, S.; Sangal, V. Epidemic Multiple Drug Resistant Salmonella Typhimurium Causing Invasive Disease in Sub-Saharan Africa Have a Distinct Genotype. Genome Res. 2009, 19, 2279–2287. [Google Scholar] [CrossRef]
  18. Reddy, E.A.; Shaw, A.V.; Crump, J.A. Community-Acquired Bloodstream Infections in Africa: A Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2010, 10, 417–432. [Google Scholar] [CrossRef]
  19. Brent, A.J.; Oundo, J.O.; Mwangi, I.; Ochola, L.; Lowe, B.; Berkley, J.A. Salmonella Bacteremia in Kenyan Children. Pediatr. Infect. Dis. J. 2006, 25, 230–236. [Google Scholar] [CrossRef]
  20. Lyamuya, M.; Nadjm, B.; Mtove, G.; Reyburn, H.; Morpeth, S.C.; Shao, J.F.; Saganda, W.; Mwako, M.; Morrissey, A.B.; Amos, B. Contrasting Epidemiology of Salmonella Typhi and Non-Typhi Salmonella Bloodstream Infections at Two Sites in Northern Tanzania. Int. J. Infect. Dis. 2008, 12, S23. [Google Scholar] [CrossRef]
  21. Smith, A.M.; Mthanti, M.A.; Haumann, C.; Tyalisi, N.; Boon, G.P.G.; Sooka, A.; Keddy, K.H. Nosocomial Outbreak of Salmonella Enterica Serovar Typhimurium Primarily Affecting a Pediatric Ward in South Africa in 2012. J. Clin. Microbiol. 2014, 52, 627–631. [Google Scholar] [CrossRef]
  22. Galán-Relaño, Á.; Valero Díaz, A.; Huerta Lorenzo, B.; Gómez-Gascón, L.; Mena Rodríguez, M.Á.; Carrasco Jiménez, E.; Pérez Rodríguez, F.; Astorga Márquez, R.J. Salmonella and Salmonellosis: An Update on Public Health Implications and Control Strategies. Animals 2023, 13, 3666. [Google Scholar] [CrossRef]
  23. Qin, X.; Yang, M.; Cai, H.; Liu, Y.; Gorris, L.; Aslam, M.Z.; Jia, K.; Sun, T.; Wang, X.; Dong, Q. Antibiotic Resistance of Salmonella Typhimurium Monophasic Variant 1,4,[5],12:i:-in China: A Systematic Review and Meta-Analysis. Antibiotics 2022, 11, 532. [Google Scholar] [CrossRef] [PubMed]
  24. Espunyes, J.; Illera, L.; Dias-Alves, A.; Lobato, L.; Ribas, M.P.; Manzanares, A.; Ayats, T.; Marco, I.; Cerdà-Cuéllar, M. Eurasian griffon vultures carry widespread antimicrobial resistant Salmonella and Campylobacter of public health concern. Sci. Total Environ. 2022, 844, 157189. [Google Scholar] [CrossRef] [PubMed]
  25. Gorski, L.; Liang, A.S.; Walker, S.; Carychao, D.; Aviles Noriega, A.; Mandrell, R.E.; Cooley, M.B. Salmonella enterica Serovar Diversity, Distribution, and Prevalence in Public-Access Waters from a Central California Coastal Leafy Green-Growing Region from 2011 to 2016. Appl. Environ. Microbiol. 2022, 88, e0183421. [Google Scholar] [CrossRef] [PubMed]
  26. Zhao, Q.Y.; Zhang, L.; Yang, J.T.; Wei, H.J.; Zhang, Y.H.; Wang, J.Y.; Liu, W.Z.; Jiang, H.X. Diversity of evolution in MDR monophasic S. Typhimurium among food animals and food products in Southern China from 2011 to 2018. Int. J. Food Microbiol. 2024, 412, 110572. [Google Scholar] [CrossRef]
  27. Plumb, I.D.; Brown, A.C.; Stokes, E.K.; Chen, J.C.; Carleton, H.; Tolar, B.; Sundararaman, P.; Saupe, A.; Payne, D.C.; Shah, H.J.; et al. Increased Multidrug-Resistant Salmonella enterica I Serotype 4,[5],12:i:- Infections Associated with Pork, United States, 2009-2018. Emerg. Infect. Dis. 2023, 29, 314–322. [Google Scholar] [CrossRef]
  28. Egan, D.A.; Naughton, V.; Dooley, J.S.; Naughton, P.J. Detection of Salmonella Enterica Serovar Rissen in Slaughter Pigs in Northern Ireland. AiM 2017, 7, 513–522. [Google Scholar] [CrossRef]
  29. Zhou, A.; Li, J.; Xu, Z.; Ni, J.; Guo, J.; Yao, Y.-F.; Wu, W. Whole-Genome Comparative and Pathogenicity Analysis of Salmonella Enterica Subsp. Enterica Serovar Rissen. G3: Genes Genomes Genet. 2020, 10, 2159–2170. [Google Scholar] [CrossRef]
  30. EFSA and ECDC (European Food Safety Authority and European Centre for Disease Prevention and Control). The European Union One Health 2021 Zoonoses Report. EFSA J. 2022, 20, e07666. [Google Scholar] [CrossRef]
  31. Prasertsee, T.; Chuammitri, P.; Deeudom, M.; Chokesajjawatee, N.; Santiyanont, P.; Tadee, P.; Nuangmek, A.; Tadee, P.; Sheppard, S.K.; Pascoe, B.; et al. Core genome sequence analysis to characterize Salmonella enterica serovar Rissen ST469 from a swine production chain. Int. J. Food Microbiol. 2019, 304, 68–74. [Google Scholar] [CrossRef]
  32. Elbediwi, M.; Shi, D.; Biswas, S.; Xu, X.; Yue, M. Changing patterns of Salmonella enterica serovar Rissen from humans, food animals, and animal-derived foods in China, 1995–2019. Front. Microbiol. 2021, 12, 702909. [Google Scholar] [CrossRef]
  33. Wang, Z.; Zhang, Y.; Xu, H.; Chu, C.; Wang, J.; Jiao, X.; Li, Q. Whole-Genome Sequencing Analysis Reveals Pig as the Main Reservoir for Persistent Evolution of Salmonella Enterica Serovar Rissen Causing Human Salmonellosis. Food Res. Int. 2022, 154, 111007. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, S.; Cheng, M.; Chen, C.-C.; Chang, C.-Y.; Tsai, Y.-C.; Yang, J.-M.; Wu, T.; Huang, C.-H.; Hung, C.-F. Salmonella Immunotherapy Engineered with Highly Efficient Tumor Antigen Coating Establishes Antigen-Specific CD8+ T Cell Immunity and Increases in Antitumor Efficacy with Type I Interferon Combination Therapy. OncoImmunology 2023, 13, 2298444. [Google Scholar] [CrossRef] [PubMed]
  35. Silveira, L.; Pinto, M.; Isidro, J.; Pista, Â.; Themudo, P.; Vieira, L.; Machado, J.; Gomes, J.P. Multidrug-Resistant Salmonella Enterica Serovar Rissen Clusters Detected in Azores Archipelago, Portugal. Int. J. Genom. 2019, 2019, 1860275. [Google Scholar] [CrossRef] [PubMed]
  36. Robinson, E.J.; Gregory, J.; Mulvenna, V.; Segal, Y.; Sullivan, S.G. Effect of Temperature and Rainfall on Sporadic Salmonellosis Notifications in Melbourne, Australia 2000–2019: A Time-Series Analysis. Foodborne Pathog. Dis. 2022, 19, 341–348. [Google Scholar] [CrossRef]
  37. Brandl, M.T.; Ivanek, R.; Allende, A.; Munther, D.S. Predictive Population Dynamics of Escherichia Coli O157:H7 and Salmonella Enterica on Plants: A Mechanistic Mathematical Model Based on Weather Parameters and Bacterial State. Appl. Envrion. Microbiol. 2023, 89, e00700-23. [Google Scholar] [CrossRef]
  38. Magossi, G.; Bai, J.; Cernicchiaro, N.; Jones, C.; Porter, E.; Trinetta, V. Seasonal Presence of Salmonella Spp., Salmonella Typhimurium and Its Monophasic Variant Serotype I 4, [5],12:I:-, In Selected United States Swine Feed Mills. Foodborne Pathog. Dis. 2019, 16, 276–281. [Google Scholar] [CrossRef]
  39. Akil, L.; Ahmad, H.A.; Reddy, R.S. Effects of climate change on Salmonella infections. Foodborne Pathog. Dis. 2014, 11, 974–980. [Google Scholar] [CrossRef]
  40. Simko, I.; Zhou, Y.; Brandl, M.T. Downy Mildew Disease Promotes the Colonization of Romaine Lettuce by Escherichia Coli O157:H7 and Salmonella Enterica. BMC Microbiol 2015, 15, 19. [Google Scholar] [CrossRef]
  41. Zwe, Y.H.; Ten, M.M.Z.; Pang, X.; Wong, C.H.; Li, D. Differential Survivability of Two Genetically Similar Salmonella Thompson Strains on Pre-Harvest Sweet Basil (Ocimum Basilicum) Leaves. Front. Microbiol. 2021, 12, 740983. [Google Scholar] [CrossRef]
  42. Anikeeva, O.; Hansen, A.; Varghese, B.; Borg, M.; Zhang, Y.; Xiang, J.; Bi, P. The impact of increasing temperatures due to climate change on infectious diseases. BMJ 2024, 387, e079343. [Google Scholar] [CrossRef]
  43. Billah, M.M.; Raham, M.S. Salmonella in the environment: A review on ecology, antimicrobial resistance, seafood contaminations, and human health implications. J. Hazard. Mater. Adv. 2024, 13, 100407. [Google Scholar] [CrossRef]
  44. Dietrich, J.; Hammerl, J.A.; Johne, A.; Kappenstein, O.; Loeffler, C.; Nöckler, K.; Rosner, B.; Spielmeyer, A.; Szabo, I.; Richter, M.H. Impact of climate change on foodborne infections and intoxications. J. Health Monit. 2023, 8 (Suppl S3), 78–92. [Google Scholar] [CrossRef] [PubMed]
  45. Black, Z.; Balta, I.; Black, L.; Naughton, P.J.; Dooley, J.S.G.; Corcionivoschi, N. The Fate of Foodborne Pathogens in Manure Treated Soil. Front. Microbiol. 2021, 12, 781357. [Google Scholar] [CrossRef]
  46. Kowalska, B. Fresh Vegetables and Fruit as a Source of Salmonella Bacteria. Ann. Agric. Envrion. Med. 2023, 30, 9–14. [Google Scholar] [CrossRef] [PubMed]
  47. Musa, L.; Toppi, V.; Stefanetti, V.; Spata, N.; Rapi, M.C.; Grilli, G.; Addis, M.F.; di Giacinto, G.; Franciosini, M.P.; Casagrande Proietti, P. High Biofilm-Forming Multidrug-Resistant Salmonella Infantis Strains from the Poultry Production Chain. Antibiotics 2024, 13, 595. [Google Scholar] [CrossRef]
  48. Ćwiek, K.; Korzekwa, K.; Tabiś, A.; Bania, J.; Bugla-Płoskońska, G.; Wieliczko, A. Antimicrobial Resistance and Biofilm Formation Capacity of Salmonella enterica Serovar Enteritidis Strains Isolated from Poultry and Humans in Poland. Pathogens 2020, 9, 643. [Google Scholar] [CrossRef]
  49. Harrell, J.E.; Hahn, M.M.; D’Souza, S.J.; Vasicek, E.M.; Sandala, J.L.; Gunn, J.S.; McLachlan, J.B. Salmonella Biofilm Formation, Chronic Infection, and Immunity Within the Intestine and Hepatobiliary Tract. Front. Cell. Infect. Microbiol. 2021, 10, 624622. [Google Scholar] [CrossRef]
  50. Jorge, P.; Magalhães, A.P.; Grainha, T.; Alves, D.; Sousa, A.M.; Lopes, S.P.; Pereira, M.O. Antimicrobial resistance three ways: Healthcare crisis, major concepts and the relevance of biofilms. FEMS Microbiol. Ecol. 2019, 95, fiz115. [Google Scholar] [CrossRef]
  51. Vestby, L.K.; Grønseth, T.; Simm, R.; Nesse, L.L. Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics 2020, 9, 59. [Google Scholar] [CrossRef]
  52. Fan, S.; Headey, D.; Rue, C.; Thomas, T. Food Systems for Human and Planetary Health: Economic Perspectives and Challenges. Annu. Rev. Resour. Econ. 2021, 13, 131–156. [Google Scholar] [CrossRef]
  53. Carrasco, E.; Morales-Rueda, A.; García-Gimeno, R.M. Cross-Contamination and Recontamination by Salmonella in Foods: A Review. Food Res. Int. 2012, 45, 545–556. [Google Scholar] [CrossRef]
  54. Byun, K.-H.; Han, S.H.; Yoon, J.; Park, S.H.; Ha, S.-D. Efficacy of Chlorine-Based Disinfectants (Sodium Hypochlorite and Chlorine Dioxide) on Salmonella Enteritidis Planktonic Cells, Biofilms on Food Contact Surfaces and Chicken Skin. Food Control 2021, 123, 107838. [Google Scholar] [CrossRef]
  55. Rossi, C.; Chaves-López, C.; Možina, S.S.; di Mattia, C.; Scuota, S.; Luzzi, I.; Jenič, T.; Paparella, A.; Serio, A. Salmonella Enterica Adhesion: Effect of Cinnamomum Zeylanicum Essential Oil on Lettuce. LWT 2019, 111, 16–22. [Google Scholar] [CrossRef]
  56. Seo, H.-J.; Kang, S.-S. Inhibitory Effect of Bacteriocin Produced by Pediococcus acidilactici on the Biofilm Formation of Salmonella Typhimurium. Food Control 2020, 117, 107361. [Google Scholar] [CrossRef]
  57. Lamas, A.; Fernandez-No, I.C.; Miranda, J.M.; Vázquez, B.; Cepeda, A.; Franco, C.M. Biofilm Formation and Morphotypes of Salmonella Enterica Subsp. Arizonae Differs from Those of Other Salmonella Enterica Subspecies in Isolates from Poultry Houses. J. Food Prot. 2016, 79, 1127–1134. [Google Scholar] [CrossRef]
  58. Fuentes, D.N.; Calderón, P.F.; Acuña, L.G.; Rodas, P.I.; Paredes-Sabja, D.; Fuentes, J.A.; Gil, F.; Calderón, I.L. Motility Modulation by the Small Non-Coding RNA SroC In SalmonellaTyphimurium. FEMS Microbiol. Lett. 2015, 362, fnv135. [Google Scholar] [CrossRef]
  59. Ryan, D.; Mukherjee, M.; Suar, M. The Expanding Targetome of Small RNAs in Salmonella Typhimurium. Biochimie 2017, 137, 69–77. [Google Scholar] [CrossRef]
  60. Lamas, A.; Paz-Mendez, A.M.; Regal, P.; Vazquez, B.; Miranda, J.M.; Cepeda, A.; Franco, C.M. Food Preservatives Influence Biofilm Formation, Gene Expression and Small RNAs in Salmonella Enterica. LWT 2018, 97, 1–8. [Google Scholar] [CrossRef]
  61. Steenackers, H.; Hermans, K.; Vanderleyden, J.; de Keersmaecker, S.C.J. Salmonella Biofilms: An Overview on Occurrence, Structure, Regulation and Eradication. Food Res. Int. 2012, 45, 502–531. [Google Scholar] [CrossRef]
  62. Gerstel, U.; Römling, U. The CsgD Promoter, a Control Unit for Biofilm Formation in Salmonella Typhimurium. Res. Microbiol. 2003, 154, 659–667. [Google Scholar] [CrossRef]
  63. Ahmad, I.; Cimdins, A.; Beske, T.; Römling, U. Detailed Analysis of C-Di-GMP Mediated Regulation of CsgD Expression in Salmonella Typhimurium. BMC Microbiol. 2017, 17, 1–12. [Google Scholar] [CrossRef] [PubMed]
  64. Sokaribo, A.S.; Hansen, E.G.; McCarthy, M.; Desin, T.S.; Waldner, L.L.; MacKenzie, K.D.; Mutwiri, G.; Herman, N.J.; Herman, D.J.; Wang, Y. Metabolic Activation of CsgD in the Regulation of Salmonella Biofilms. Microorganisms 2020, 8, 964. [Google Scholar] [CrossRef] [PubMed]
  65. Monte, J.; Abreu, A.; Borges, A.; Simões, L.; Simões, M. Antimicrobial Activity of Selected Phytochemicals against Escherichia coli and Staphylococcus aureus and Their Biofilms. Pathogens 2014, 3, 473–498. [Google Scholar] [CrossRef]
  66. Seixas, R.; Machado, J.; Bernardo, F.; Vilela, C.; Oliveira, M. Biofilm Formation by Salmonella Enterica Serovar 1,4,[5],12:I:- Portuguese Isolates: A Phenotypic, Genotypic, and Socio-Geographic Analysis. Curr. Microbiol. 2014, 68, 670–677. [Google Scholar] [CrossRef]
  67. Seixas, R.; Santos, T.R.; Machado, J.; Tavares, L.; Bernardo, F.; Semedo-Lemsaddek, T.; Oliveira, M. Phenotypic and Molecular Characterization Of Salmonella1,4,[5],12:I:- R-Type ASSuT Isolates from Humans, Animals, and Environment in Portugal, 2006–2011. Foodborne Pathog. Dis. 2016, 13, 633–641. [Google Scholar] [CrossRef]
  68. Dwyer, B.E.; Newton, K.L.; Kisiela, D.; Sokurenko, E.V.; Clegg, S. Single Nucleotide Polypmorphisms of FimH Associated with Adherence and Biofilm Formation by Serovars of Salmonella Enterica. Microbiology 2011, 157, 3162–3171. [Google Scholar] [CrossRef]
  69. Latasa, C.; Roux, A.; Toledo-Arana, A.; Ghigo, J.; Gamazo, C.; Penadés, J.R.; Lasa, I. BapA, a Large Secreted Protein Required for Biofilm Formation and Host Colonization of Salmonella Enterica Serovar Enteritidis. Mol. Microbiol. 2005, 58, 1322–1339. [Google Scholar] [CrossRef]
  70. Guttula, D.; Yao, M.; Baker, K.; Yang, L.; Goult, B.T.; Doyle, P.S.; Yan, J. Calcium-Mediated Protein Folding and Stabilization of Salmonella Biofilm-Associated Protein A. J. Mol. Biol. 2019, 431, 433–443. [Google Scholar] [CrossRef]
  71. Pradhan, J.; Pradhan, D.; Sahu, J.K.; Mishra, S.; Mallick, S.; Das, S.; Negi, V.D. A Novel RspA Gene Regulates Biofilm Formation and Virulence of Salmonella Typhimurium. Microb. Pathog. 2023, 185, 106432. [Google Scholar] [CrossRef]
  72. Von Hertwig, A.M.; Prestes, F.S.; Nascimento, M.S. Biofilm Formation and Resistance to Sanitizers by Salmonella Spp. Isolated from the Peanut Supply Chain. Food Res. Int. 2022, 152, 110882. [Google Scholar] [CrossRef]
  73. Beuchat, L.R.; Komitopoulou, E.; Beckers, H.; Betta, R.P.; Bourdichon, F.; Fanning, S.; Joosten, H.M.; Ter Kuile, B.H. Low-water activity foods: Increased concern as vehicles of foodborne pathogens. J. Food Prot. 2013, 76, 150–172. [Google Scholar] [CrossRef] [PubMed]
  74. Finn, S.; Condell, O.; McClure, P.; Amézquita, A.; Fanning, S. Mechanisms of Survival, Responses and Sources of Salmonella in Low-Moisture Environments. Front. Microbiol. 2013, 4, 331. [Google Scholar] [CrossRef] [PubMed]
  75. Podolak, R.; Enache, E.; Stone, W.; Black, D.G.; Elliott, P.H. Sources and Risk Factors for Contamination, Survival, Persistence, and Heat Resistance of Salmonella in Low-Moisture Foods. J. Food Prot. 2010, 73, 1919–1936. [Google Scholar] [CrossRef] [PubMed]
  76. Kim, S.-H.; Wei, C.-I. Biofilm Formation by Multidrug-Resistant Salmonella Enterica Serotype Typhimurium Phage Type DT104 and Other Pathogens. J. Food Prot. 2007, 70, 22–29. [Google Scholar] [CrossRef]
  77. Solano, C.; García, B.; Valle, J.; Berasain, C.; Ghigo, J.; Gamazo, C.; Lasa, I. Genetic Analysis of Salmonella Enteritidis Biofilm Formation: Critical Role of Cellulose. Mol. Microbiol. 2002, 43, 793–808. [Google Scholar] [CrossRef]
  78. Lee, S.; Chen, J. Genes of Salmonella Enterica Serovar Enteritidis Involved in Biofilm Formation. Appl. Microbiol. 2024, 4, 771–781. [Google Scholar] [CrossRef]
  79. Chen, J.; Wang, Y. Genetic Determinants of Salmonella Enterica Critical for Attachment and Biofilm Formation. Int. J. Food Microbiol. 2020, 320, 108524. [Google Scholar] [CrossRef]
  80. Eran, Z.; Akçelik, M.; Yazıcı, B.C.; Özcengiz, G.; Akçelik, N. Regulation of Biofilm Formation by MarT in Salmonella Typhimurium. Mol. Biol. Rep. 2020, 47, 5041–5050. [Google Scholar] [CrossRef]
  81. Hahn, M.M.; Gunn, J.S. Salmonella Extracellular Polymeric Substances Modulate Innate Phagocyte Activity and Enhance Tolerance of Biofilm-Associated Bacteria to Oxidative Stress. Microorganisms 2020, 8, 253. [Google Scholar] [CrossRef]
  82. Simm, R.; Ahmad, I.; Rhen, M.; Le Guyon, S.; Römling, U. Regulation of Biofilm Formation in Salmonella Enterica Serovar Typhimurium. Future Microbiol. 2014, 9, 1261–1282. [Google Scholar] [CrossRef]
  83. Gonzalez-Escobedo, G.; Marshall, J.M.; Gunn, J.S. Chronic and Acute Infection of the Gall Bladder by Salmonella Typhi: Understanding the Carrier State. Nat. Rev. Microbiol. 2011, 9, 9–14. [Google Scholar] [CrossRef] [PubMed]
  84. Gunn, J.S.; Marshall, J.M.; Baker, S.; Dongol, S.; Charles, R.C.; Ryan, E.T. Salmonella Chronic Carriage: Epidemiology, Diagnosis, and Gallbladder Persistence. Trends Microbiol. 2014, 22, 648–655. [Google Scholar] [CrossRef] [PubMed]
  85. Marshall, J.M.; Flechtner, A.D.; La Perle, K.M.; Gunn, J.S. Visualization of Extracellular Matrix Components within Sectioned Salmonella Biofilms on the Surface of Human Gallstones. PLoS ONE 2014, 9, e89243. [Google Scholar] [CrossRef] [PubMed]
  86. Crawford, R.W.; Rosales-Reyes, R.; Ramírez-Aguilar, M.d.l.L.; Chapa-Azuela, O.; Alpuche-Aranda, C.; Gunn, J.S. Gallstones Play a Significant Role in Salmonella Spp. Gallbladder Colonization and Carriage. Proc. Natl. Acad. Sci. USA 2010, 107, 4353–4358. [Google Scholar] [CrossRef]
  87. Crawford, R.W.; Reeve, K.E.; Gunn, J.S. Flagellated but Not Hyperfimbriated Salmonella Enterica Serovar Typhimurium Attaches to and Forms Biofilms on Cholesterol-Coated Surfaces. J. Bacteriol. 2010, 192, 2981–2990. [Google Scholar] [CrossRef]
  88. Gonzalez-Escobedo, G.; Gunn, J.S. Identification of Salmonella Enterica Serovar Typhimurium Genes Regulated during Biofilm Formation on Cholesterol Gallstone Surfaces. Infect. Immun. 2013, 81, 3770–3780. [Google Scholar] [CrossRef]
  89. Tsai, M.-H.; Liang, Y.-H.; Chen, C.-L.; Chiu, C.-H. Characterization of Salmonella Resistance to Bile during Biofilm Formation. J. Microbiol. Immunol. Infect. 2020, 53, 518–524. [Google Scholar] [CrossRef]
  90. González, J.F.; Hahn, M.M.; Gunn, J.S. Chronic biofilm-based infections: Skewing of the immune response. Pathog. Dis. 2018, 76, fty023. [Google Scholar] [CrossRef]
  91. Ehrhardt, K.; Becker, A.-L.; Grassl, G.G. Determinants of persistent Salmonella infections. Curr. Opin. Immunol. 2023, 82, 102306. [Google Scholar] [CrossRef]
  92. Desai, S.K.; Zhou, Y.; Dilawari, R.; Routh, A.L.; Popov, V.; Kenney, L.J. RpoS Activates Formation of Salmonella Typhi Biofilms and Drives Persistence in the Gall Bladder. bioRxiv 2024. [Google Scholar] [CrossRef]
  93. Di Domenico, E.G.; Cavallo, I.; Pontone, M.; Toma, L.; Ensoli, F. Biofilm Producing Salmonella Typhi: Chronic Colonization and Development of Gallbladder Cancer. Int. J. Mol. Sci. 2017, 18, 1887. [Google Scholar] [CrossRef] [PubMed]
  94. Scanu, T.; Spaapen, R.M.; Bakker, J.M.; Pratap, C.B.; Wu, L.; Hofland, I.; Broeks, A.; Shukla, V.K.; Kumar, M.; Janssen, H. Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma. Cell Host Microbe 2015, 17, 763–774. [Google Scholar] [CrossRef] [PubMed]
  95. Hoffman, S.A.; Sikorski, M.J.; Levine, M.M. Chronic Salmonella Typhi Carriage at Sites Other than the Gallbladder. PLoS. Negl. Trop Dis. 2023, 17, e0011168. [Google Scholar] [CrossRef] [PubMed]
  96. Solano, C.; Sesma, B.; Alvarez, M.; Urdaneta, E.; Garcia-Ros, D.; Calvo, A.; Gamazo, C. Virulent Strains of Salmonella Enteritidis Disrupt the Epithelial Barrier of Caco-2 and HEp-2 Cells. Arch. Microbiol. 2001, 175, 46–51. [Google Scholar] [CrossRef] [PubMed]
  97. Ledeboer, N.A.; Jones, B.D. Exopolysaccharide Sugars Contribute to Biofilm Formation by Salmonella Enterica Serovar Typhimurium on HEp-2 Cells and Chicken Intestinal Epithelium. J. Bacteriol. 2005, 187, 3214–3226. [Google Scholar] [CrossRef]
  98. Ledeboer, N.A.; Frye, J.G.; McClelland, M.; Jones, B.D. Salmonella Enterica Serovar Typhimurium Requires the Lpf, Pef, and Tafi Fimbriae for Biofilm Formation on HEp-2 Tissue Culture Cells and Chicken Intestinal Epithelium. Infect. Immun. 2006, 74, 3156–3169. [Google Scholar] [CrossRef]
  99. Lamprokostopoulou, A.; Monteiro, C.; Rhen, M.; Römling, U. Cyclic Di-GMP Signalling Controls Virulence Properties of Salmonella enterica serovar Typhimurium at the Mucosal Lining. Environ. Microbiol. 2010, 12, 40–53. [Google Scholar] [CrossRef]
  100. Lamprokostopoulou, A.; Römling, U. Yin and Yang of Biofilm Formation and Cyclic Di-GMP Signaling of the Gastrointestinal Pathogen Salmonella enterica Serovar Typhimurium. J. Innate Immun. 2022, 14, 275–292. [Google Scholar] [CrossRef]
  101. Lam, L.H.; Monack, D.M. Intraspecies Competition for Niches in the Distal Gut Dictate Transmission during Persistent Salmonella Infection. PLoS. Pathog. 2014, 10, e1004527. [Google Scholar] [CrossRef]
  102. Desai, S.K.; Kenney, L.J. Switching lifestyles is an in vivo Adaptive Strategy of Bacterial Pathogens. Front. Cell. Infect. Microbiol. 2019, 9, 421. [Google Scholar] [CrossRef]
  103. Desai, S.K.; Padmanabhan, A.; Harshe, S.; Zaidel-Bar, R.; Kenney, L.J. Salmonella Biofilms Program Innate Immunity for Persistence in Caenorhabditis Elegans. Proc. Natl. Acad. Sci. USA 2019, 116, 12462–12467. [Google Scholar] [CrossRef] [PubMed]
  104. Marzel, A.; Desai, P.T.; Goren, A.; Schorr, Y.I.; Nissan, I.; Porwollik, S.; Valinsky, L.; McClelland, M.; Rahav, G.; Gal-Mor, O. Persistent Infections by Non typhoidal Salmonella in Humans: Epidemiology and Genetics. Clin. Infect. Dis. 2016, 62, 879–886. [Google Scholar] [CrossRef] [PubMed]
  105. Barnhart, M.M.; Chapman, M.R. Curli Biogenesis and Function. Annu. Rev. Microbiol. 2006, 60, 131–147. [Google Scholar] [CrossRef] [PubMed]
  106. Tursi, S.A.; Tükel, Ç. Curli-Containing Enteric Biofilms Inside and Out: Matrix Composition, Immune Recognition, and Disease Implications. Microbiol. Mol. Biol. Rev. 2018, 82, 10–1128. [Google Scholar] [CrossRef]
  107. Kao, S.; Serfecz, J.; Sudhakar, A.; Likosky, K.; Romiyo, V.; Tursi, S.; Tükel, Ç.; Wilson, J.W. Salmonella Enterica serovar Typhimurium STM1266 Encodes a Regulator of Curli Biofilm Formation: : the brfS gene. FEMS Microbiol. Lett. 2023, 370, fnad012. [Google Scholar] [CrossRef]
  108. Miller, A.L.; Bessho, S.; Grando, K.; Tükel, Ç. Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Front. Immunol. 2021, 12, 638867. [Google Scholar] [CrossRef]
  109. McAnearney, S.; McCall, D. Salmonella Osteomyelitis. Ulst. Med. J. 2015, 84, 171–172. [Google Scholar] [PubMed] [PubMed Central]
  110. Huang, Z.; Wang, C.; Shi, T.; Wu, B.; Chen, Y.; Li, W.; Fang, X.; Zhang, W. Salmonella Osteomyelitis in Adults: A Systematic Review. Orthop. Surg. 2021, 13, 1135–1140. [Google Scholar] [CrossRef]
  111. McLeod, N.; Lastinger, A.; Bryan, N.; Kieffer, T.; Wolfe, T. Salmonella Neck Abscess in a Diabetic. IDCases 2019, 17, e00541. [Google Scholar] [CrossRef]
  112. Tu, T.-Y.; Yeh, C.-Y.; Hung, Y.-M.; Chang, R.; Chen, H.-H.; Wei, J.C.-C. Association Between a History of Nontyphoidal Salmonella and the Risk of Systemic Lupus Erythematosus: A Population-Based, Case-Control Study. Front. Immunol. 2021, 12, 725996. [Google Scholar] [CrossRef]
  113. Hedrich, C.M.; Hofmann, S.R.; Pablik, J.; Morbach, H.; Girschick, H.J. Autoinflammatory Bone Disorders with Special Focus on Chronic Recurrent Multifocal Osteomyelitis (CRMO). Pediatr. Rheumatol. 2013, 11, 47. [Google Scholar] [CrossRef] [PubMed]
  114. Taddio, A.; Ferrara, G.; Insalaco, A.; Pardeo, M.; Gregori, M.; Finetti, M.; Pastore, S.; Tommasini, A.; Ventura, A.; Gattorno, M. Dealing with Chronic Non-Bacterial Osteomyelitis: A Practical Approach. Pediatr. Rheumatol. 2017, 15, 87. [Google Scholar] [CrossRef] [PubMed]
  115. El Hag, M.; Feng, Z.; Su, Y.; Wang, X.; Yassin, A.; Chen, S.; Peng, D.; Liu, X. Contribution of the CsgA and BcsA Genes to Salmonella Enterica Serovar Pullorum Biofilm Formation and Virulence. Avian Pathol. 2017, 46, 541–547. [Google Scholar] [CrossRef]
  116. Olubisose, E.T.; Ajayi, A.; Adeleye, A.I.; Smith, S.I. Molecular and Phenotypic Characterization of Efflux Pump and Biofilm in Multi-Drug Resistant Non-Typhoidal Salmonella Serovars Isolated from Food Animals and Handlers in Lagos Nigeria. One Health Outlook 2021, 3, 2. [Google Scholar] [CrossRef]
  117. Lin, I.; Van, T.; Smooker, P. Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery. Vaccines 2015, 3, 940–972. [Google Scholar] [CrossRef]
  118. Cheminay, C.; Hensel, M. Rational Design of Salmonella Recombinant Vaccines. Int. J. Med. Microbiol. 2008, 298, 87–98. [Google Scholar] [CrossRef]
  119. Lavelle, E.C.; Ward, R.W. Mucosal Vaccines—Fortifying the Frontiers. Nat. Rev. Immunol. 2022, 22, 236–250. [Google Scholar] [CrossRef]
  120. Kong, W.; Brovold, M.; Koeneman, B.A.; Clark-Curtiss, J.; Curtiss, R. Turning Self-Destructing Salmonella into a Universal DNA Vaccine Delivery Platform. Proc. Natl. Acad. Sci. USA 2012, 109, 19414–19419. [Google Scholar] [CrossRef]
  121. Chiu, T.-W.; Peng, C.-J.; Chen, M.-C.; Hsu, M.-H.; Liang, Y.-H.; Chiu, C.-H.; Fang, J.-M.; Lee, Y.C. Constructing Conjugate Vaccine against Salmonella Typhimurium Using Lipid-A Free Lipopolysaccharide. J. Biomed. Sci. 2020, 27, 89. [Google Scholar] [CrossRef]
  122. Shah, P.K.; Chyu, K.-Y.; Dimayuga, P.C.; Nilsson, J. Vaccine for Atherosclerosis. J. Am. Coll. Cardiol. 2014, 64, 2779–2791. [Google Scholar] [CrossRef]
  123. Yurina, V. Live Bacterial Vectors—A Promising DNA Vaccine Delivery System. Med. Sci. 2018, 6, 27. [Google Scholar] [CrossRef] [PubMed]
  124. Hauer, A.D.; van Puijvelde, G.H.M.; Peterse, N.; de Vos, P.; van Weel, V.; van Wanrooij, E.J.A.; Biessen, E.A.L.; Quax, P.H.A.; Niethammer, A.G.; Reisfeld, R.A. Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis. ATVB 2007, 27, 2050–2057. [Google Scholar] [CrossRef]
  125. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006, 26, 154–158. [Google Scholar] [PubMed] [PubMed Central]
  126. Avogadri, F.; Martinoli, C.; Petrovska, L.; Chiodoni, C.; Transidico, P.; Bronte, V.; Longhi, R.; Colombo, M.P.; Dougan, G.; Rescigno, M. Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. Cancer Res. 2005, 65, 3920–3927. [Google Scholar] [CrossRef]
  127. Levine, P.; Gould-Suarez, M. Colorectal Cancer Screening Recommendations. JAMA 2016, 316, 1715. [Google Scholar] [CrossRef]
  128. Duijster, J.; Mughini-Gras, L.; Franz, E.; Neefjes, J. RF-298 Occupational Risk of Salmonellosis and Campylobacteriosis: A Nationwide Population-Based Registry study. Occup. Environ. Med. 2021, 78, A144–A145. [Google Scholar]
  129. Liang, K.; Tian, Z.; Chen, X.; Li, M.; Zhang, X.; Bian, X.; Ali, M.K.; Kong, Q. Attenuated Salmonella Typhimurium with Truncated LPS and Outer Membrane-Displayed RGD Peptide for Cancer Therapy. Biomed. Pharmacother. 2022, 155, 113682. [Google Scholar] [CrossRef]
  130. Aganja, R.P.; Sivasankar, C.; Senevirathne, A.; Lee, J.H. Salmonella as a Promising Curative Tool against Cancer. Pharmaceutics 2022, 14, 2100. [Google Scholar] [CrossRef]
  131. Van Elsland, D.M.; Duijster, J.W.; Zhang, J.; Stévenin, V.; Zhang, Y.; Zha, L.; Xia, Y.; Franz, E.; Sun, J.; Mughini-Gras, L. Repetitive Non-Typhoidal Salmonella Exposure Is an Environmental Risk Factor for Colon Cancer and Tumor Growth. Cell Rep. Med. 2022, 3, 100852. [Google Scholar] [CrossRef]
  132. Shanker, E.B.; Sun, J. Salmonella Infection Acts as an Environmental Risk Factor for Human Colon Cancer. Cell Insight 2023, 2, 100125. [Google Scholar] [CrossRef]
  133. Mi, Z.; Feng, Z.C.; Li, C.; Yang, X.; Ma, M.T.; Rong, P.F. Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy. J. Cancer 2019, 10, 4765–4776. [Google Scholar] [CrossRef] [PubMed]
  134. Badie, F.; Ghandali, M.; Tabatabaei, S.A.; Safari, M.; Khorshidi, A.; Shayestehpour, M.; Mahjoubin-Tehran, M.; Morshedi, K.; Jalili, A.; Tajiknia, V.; et al. Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches. Front. Oncol. 2021, 11, 624759. [Google Scholar] [CrossRef]
  135. Wang, D.; Wei, X.; Kalvakolanu, D.V.; Guo, B.; Zhang, L. Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy. Front. Immunol. 2021, 12, 615930. [Google Scholar] [CrossRef] [PubMed]
  136. Felgner, S.; Kocijancic, D.; Pawar, V.; Weiss, S. Biomimetic Salmonella: A Next-Generation Therapeutic Vector? Trends Microbiol. 2016, 24, 850–852. [Google Scholar] [CrossRef] [PubMed]
  137. Felgner, S.; Kocijancic, D.; Frahm, M.; Curtiss, R.; Erhardt, M.; Weiss, S. OptimizingSalmonella Entericaserovar Typhimurium for Bacteria-Mediated Tumor Therapy. Gut Microbes 2016, 7, 171–177. [Google Scholar] [CrossRef]
  138. Felgner, S.; Kocijancic, D.; Frahm, M.; Heise, U.; Rohde, M.; Zimmermann, K.; Falk, C.; Erhardt, M.; Weiss, S. Engineered Salmonella Enterica Serovar Typhimurium Overcomes Limitations of Anti-Bacterial Immunity in Bacteria-Mediated Tumor Therapy. OncoImmunology 2018, 7, e1382791. [Google Scholar] [CrossRef]
  139. Wang, C.-Z.; Kazmierczak, R.A.; Eisenstark, A. Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy. Int. J. Microbiol. 2016, 2016, 5678702. [Google Scholar] [CrossRef]
  140. Chang, W.W.; Lai, C.H.; Chen, M.C.; Liu, C.F.; Kuan, Y.D.; Lin, S.T.; Lee, C.H. Salmonella enhance chemosensitivity in tumor through connexin 43 upregulation. Int. J. Cancer 2013, 133, 1926–1935. [Google Scholar] [CrossRef]
  141. Lee, C.H.; Wu, C.L.; Shiau, A.L. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int. J. Cancer 2008, 122, 930–935. [Google Scholar] [CrossRef]
  142. Broadway, K.M.; Denson, E.A.P.; Jensen, R.V.; Scharf, B.E. Rescuing Chemotaxis of the Anticancer Agent Salmonella Enterica Serovar Typhimurium VNP20009. J. Biotechnol. 2015, 211, 117–120. [Google Scholar] [CrossRef]
  143. Hoffman, R.M.; Zhao, M. Methods for Tumor Targeting with Salmonella Typhimurium A1-R. In Bacterial Therapy of Cancer: Methods and Protocols; Humana Press: New York, NY, USA, 2016; pp. 143–164. [Google Scholar] [CrossRef]
  144. Jia, L.-J.; Xu, H.-M.; Ma, D.-Y.; Hu, Q.-G.; Huang, X.-F.; Jiang, W.-H.; Li, S.-F.; Jia, K.-Z.; Huang, Q.-L.; Hua, Z.-C. Enhanced Therapeutic Effect by Combination of Tumor-Targeting Salmonella and Endostatin in Murine Melanoma Model. Cancer Biol. Ther. 2005, 4, 840–845. [Google Scholar] [CrossRef] [PubMed]
  145. Horiuchi, Y.; Nakamura, A.; Imai, T.; Murakami, T. Infection of Tumor Cells with Salmonella Typhimurium Mimics Immunogenic Cell Death and Elicits Tumor-Specific Immune Responses. PNAS Nexus 2023, 3, pgad484. [Google Scholar] [CrossRef] [PubMed]
  146. Pérez Jorge, G.; Gontijo, M.T.P.; Brocchi, M. Salmonella Enterica and Outer Membrane Vesicles Are Current and Future Options for Cancer Treatment. Front. Cell. Infect. Microbiol. 2023, 13, 1293351. [Google Scholar] [CrossRef] [PubMed]
  147. Pangilinan, C.R.; Lee, C.-H. Highlights of Immunomodulation in Salmonella-Based Cancer Therapy. Biomedicines 2021, 9, 1566. [Google Scholar] [CrossRef]
  148. Tan, W.; Duong, M.T.-Q.; Zuo, C.; Qin, Y.; Zhang, Y.; Guo, Y.; Hong, Y.; Zheng, J.H.; Min, J.-J. Targeting of Pancreatic Cancer Cells and Stromal Cells Using Engineered Oncolytic Salmonella Typhimurium. Mol. Ther. 2022, 30, 662–671. [Google Scholar] [CrossRef]
  149. Zheng, J.H.; Nguyen, V.H.; Jiang, S.-N.; Park, S.-H.; Tan, W.; Hong, S.H.; Shin, M.G.; Chung, I.-J.; Hong, Y.; Bom, H.-S. Two-Step Enhanced Cancer Immunotherapy with Engineered Salmonella Typhimurium Secreting Heterologous Flagellin. Sci. Transl. Med. 2017, 9, eaak9537. [Google Scholar] [CrossRef]
  150. Al-Saafeen, B.H.; Al-Sbiei, A.; Bashir, G.; Mohamed, Y.A.; Masad, R.J.; Fernandez-Cabezudo, M.J.; al-Ramadi, B.K. Attenuated Salmonella Potentiate PD-L1 Blockade Immunotherapy in a Preclinical Model of Colorectal Cancer. Front. Immunol. 2022, 13, 1017780. [Google Scholar] [CrossRef]
  151. Senevirathne, A.; Hajam, I.A. Exploring the Potential of Salmonella-Mediated Anti-Sense RCAS1 RNA Therapy in Combatting Aggressive Breast Cancer. Mol. Ther. Nucleic Acids 2024, 35, 102089. [Google Scholar] [CrossRef]
  152. Ruby, T.; McLaughlin, L.; Gopinath, S.; Monack, D. Salmonella’s Long-Term Relationship with Its Host. FEMS Microbiol. Rev. 2012, 36, 600–615. [Google Scholar] [CrossRef]
  153. Alfaqeer, N.; Wall, D. Enhancing the Natural Toxicity of Salmonella Typhimurium towards Tumours. Access Microbiol. 2020, 2, 349. [Google Scholar] [CrossRef]
  154. Leschner, S.; Weiss, S. Salmonella—Allies in the Fight against Cancer. J. Mol. Med. 2010, 88, 763–773. [Google Scholar] [CrossRef] [PubMed]
  155. Leschner, S.; Westphal, K.; Dietrich, N.; Viegas, N.; Jablonska, J.; Lyszkiewicz, M.; Lienenklaus, S.; Falk, W.; Gekara, N.; Loessner, H. Tumor Invasion of Salmonella Enterica Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF-α. PLoS ONE 2009, 4, e6692. [Google Scholar] [CrossRef] [PubMed]
  156. Roe, J.M.; Seely, K.; Bussard, C.J.; Eischen Martin, E.; Mouw, E.G.; Bayles, K.W.; Hollingsworth, M.A.; Brooks, A.E.; Dailey, K.M. Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria. Pharmaceutics 2023, 15, 2004. [Google Scholar] [CrossRef] [PubMed]
  157. Kocijancic, D.; Felgner, S.; Schauer, T.; Frahm, M.; Heise, U.; Zimmermann, K.; Erhardt, M.; Weiss, S. Local Application of Bacteria Improves Safety of Salmonella-Mediated Tumor Therapy and Retains Advantages of Systemic Infection. Oncotarget 2017, 8, 49988–50001. [Google Scholar] [CrossRef]
  158. Kocijancic, D.; Leschner, S.; Felgner, S.; Komoll, R.-M.; Frahm, M.; Pawar, V.; Weiss, S. Therapeutic Benefit of Salmonella Attributed to LPS and TNF-α Is Exhaustible and Dictated by Tumor Susceptibility. Oncotarget 2017, 8, 36492–36508. [Google Scholar] [CrossRef]
  159. Frahm, M.; Felgner, S.; Kocijancic, D.; Rohde, M.; Hensel, M.; Curtiss, R.; Erhardt, M.; Weiss, S. Efficiency of Conditionally Attenuated Salmonella Enterica Serovar Typhimurium in Bacterium-Mediated Tumor Therapy. mBio 2015, 6, 10–1128. [Google Scholar] [CrossRef]
  160. Zhang, Y.; Cao, W.; Toneri, M.; Zhang, N.; Kiyuna, T.; Murakami, T.; Nelson, S.D.; Dry, S.M.; Li, Y.; Li, S. Toxicology and Efficacy of Tumor-Targeting Salmonella Typhimurium A1-R Compared to VNP 20009 in a Syngeneic Mouse Tumor Model in Immunocompetent Mice. Oncotarget 2017, 8, 54616–54628. [Google Scholar] [CrossRef]
  161. Renteria-Flores, F.I.; García-Chagollán, M.; Jave-Suárez, L.F. Bactofection, Bacterial-Mediated Vaccination, and Cancer Therapy: Current Applications and Future Perspectives. Vaccines 2024, 12, 968. [Google Scholar] [CrossRef]
  162. NCT01099631 IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread. Available online: https://www.clinicaltrials.gov/study/NCT01099631 (accessed on 28 October 2024).
  163. Raman, V.; Howell, L.M.; Bloom, S.M.K.; Hall, C.L.; Wetherby, V.E.; Minter, L.M.; Kulkarni, A.A.; Forbes, N.S. Intracellular Salmonella Delivery of an Exogenous Immunization Antigen Refocuses CD8 T Cells against Cancer Cells, Eliminates Pancreatic Tumors and Forms Antitumor Immunity. Front. Immunol. 2023, 14, 1228532. [Google Scholar] [CrossRef]
  164. Zha, L.; Garrett, S.; Sun, J. Salmonella Infection in Chronic Inflammation and Gastrointestinal Cancer. Diseases 2019, 7, 28. [Google Scholar] [CrossRef]
  165. Massa, P.E.; Paniccia, A.; Monegal, A.; de Marco, A.; Rescigno, M. Salmonella Engineered to Express CD20-Targeting Antibodies and a Drug-Converting Enzyme Can Eradicate Human Lymphomas. Blood J. Am. Soc. Hematol. 2013, 122, 705–714. [Google Scholar] [CrossRef] [PubMed]
  166. Zhou, D.-X.; Wang, X.-H.; Xu, X.; Chen, W.-J.; Wei, J.; Chen, T.-T.; Wei, H. Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-MPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. Pharmaceutics 2022, 14, 2789. [Google Scholar] [CrossRef] [PubMed]
  167. Pawelek, J.M.; Low, K.B.; Bermudes, D. Tumor-Targeted Salmonella as a Novel Anti-Melanoma Vector. Melanoma Res. 1997, 7 (Suppl. S1), S141. [Google Scholar] [CrossRef]
  168. Low, K.B.; Murray, S.R.; Pawelek, J.; Bermudes, D. Isolation and Analysis of Suppressor Mutations in Tumor-Targeted MsbB Salmonella. In Bacterial Therapy of Cancer: Methods and Protocols; Humana Press: New York, NY, USA, 2016; pp. 95–123. [Google Scholar] [CrossRef]
  169. Tang, W.; He, Y.; Zhou, S.; Ma, Y.; Liu, G. A Novel Bifidobacterium Infantis-Mediated TK/GCV Suicide Gene Therapy System Exhibits Antitumor Activity in a Rat Model of Bladder Cancer. J. Exp. Clin. Cancer Res. 2009, 28, 155. [Google Scholar] [CrossRef]
  170. Zhou, S.; Lin, Y.; Zhao, Z.; Lai, Y.; Lu, M.; Shao, Z.; Mo, X.; Mu, Y.; Liang, Z.; Wang, X. Targeted Deprivation of Methionine with Engineered Salmonella Leads to Oncolysis and Suppression of Metastasis in Broad Types of Animal Tumor Models. Cell Rep. Med. 2023, 4, 101070. [Google Scholar] [CrossRef]
  171. Thorburn, A. Death Receptor-Induced Cell Killing. Cell. Signal. 2004, 16, 139–144. [Google Scholar] [CrossRef]
  172. Thorburn, J.; Moore, F.; Rao, A.; Barclay, W.W.; Thomas, L.R.; Grant, K.W.; Cramer, S.D.; Thorburn, A. Selective Inactivation of a Fas-Associated Death Domain Protein (FADD)-Dependent Apoptosis and Autophagy Pathway in Immortal Epithelial Cells. MBoC 2005, 16, 1189–1199. [Google Scholar] [CrossRef]
  173. Loeffler, M.; Le’Negrate, G.; Krajewska, M.; Reed, J.C. Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand. J. Natl. Cancer Inst. 2008, 100, 1113–1116. [Google Scholar] [CrossRef]
  174. Chen, J.; Wei, D.; Zhuang, H.; Qiao, Y.; Tang, B.; Zhang, X.; Wei, J.; Fang, S.; Chen, G.; Du, P. Proteomic Screening of Anaerobically Regulated Promoters from Salmonella and Its Antitumor Applications. Mol. Cell. Proteom. 2011, 10, M111.009399. [Google Scholar] [CrossRef]
  175. Chen, J.; Yang, B.; Cheng, X.; Qiao, Y.; Tang, B.; Chen, G.; Wei, J.; Liu, X.; Cheng, W.; Du, P. Salmonella-Mediated Tumor-Targeting TRAIL Gene Therapy Significantly Suppresses Melanoma Growth in Mouse Model. Cancer Sci. 2012, 103, 325–333. [Google Scholar] [CrossRef]
  176. Chen, T.; Zhao, X.; Ren, Y.; Wang, Y.; Tang, X.; Tian, P.; Wang, H.; Xin, H. Triptolide Modulates Tumour-Colonisation and Anti-Tumour Effect of Attenuated Salmonella Encoding DNase I. Appl. Microbiol. Biotechnol. 2019, 103, 929–939. [Google Scholar] [CrossRef] [PubMed]
  177. Ryan, R.M.; Green, J.; Williams, P.J.; Tazzyman, S.; Hunt, S.; Harmey, J.H.; Kehoe, S.C.; Lewis, C.E. Bacterial Delivery of a Novel Cytolysin to Hypoxic Areas of Solid Tumors. Gene Ther. 2009, 16, 329–339. [Google Scholar] [CrossRef] [PubMed]
  178. Guan, G.; Zhao, M.; Liu, L.; Jin, C.; Sun, K.; Zhang, D.; Yu, D.; Cao, H.; Lu, Y.-Q.; Wen, L. Salmonella Typhimurium Mediated Delivery of Apoptin in Human Laryngeal Cancer. Int. J. Med. Sci. 2013, 10, 1639–1648. [Google Scholar] [CrossRef] [PubMed]
  179. Xiong, D.; Song, L.; Chen, Y.; Jiao, X.; Pan, Z. Salmonella Enteritidis Activates Inflammatory Storm via SPI-1 and SPI-2 to Promote Intracellular Proliferation and Bacterial Virulence. Front. Cell. Infect. Microbiol. 2023, 13, 1158888. [Google Scholar] [CrossRef]
  180. Lu, X.; Qin, W.; Li, J.; Tan, N.; Pan, D.; Zhang, H.; Xie, L.; Yao, G.; Shu, H.; Yao, M. The Growth and Metastasis of Human Hepatocellular Carcinoma Xenografts Are Inhibited by Small Interfering RNA Targeting to the Subunit ATP6L of Proton Pump. Cancer Res. 2005, 65, 6843–6849. [Google Scholar] [CrossRef]
  181. Xiang, S.; Keates, A.C.; Fruehauf, J.; Yang, Y.; Guo, H.; Nguyen, T.; Li, C.J. In Vitro and In Vivo Gene Silencing by TransKingdom RNAi (TkRNAi). In siRNA and miRNA Gene Silencing: From Bench to Bedside; Humana Press: New York, NY, USA, 2009; pp. 1–14. [Google Scholar] [CrossRef]
  182. Jiang, Z.; Zhao, P.; Zhou, Z.; Liu, J.; Qin, L.; Wang, H. Using Attenuated Salmonella Typhi as Tumor Targeting Vector for MDR1 SiRNA Delivery: An Experimental Study. Cancer Biol. Ther. 2007, 6, 555–560. [Google Scholar] [CrossRef]
  183. Lu, R.; Wu, S.; Zhang, Y.; Xia, Y.; Zhou, Z.; Kato, I.; Dong, H.; Bissonnette, M.; Sun, J. Salmonella Protein AvrA Activates the STAT3 Signalling Pathway in Colon Cancer. Neoplasia 2016, 18, 307–316. [Google Scholar] [CrossRef]
  184. Cheng, X.; Zhang, X.; Zhou, Y.; Zhang, C.; Hua, Z.-C. A Salmonella Typhimurium Mutant Strain Capable of RNAi Delivery. Cancer Biol. Ther. 2014, 15, 1068–1076. [Google Scholar] [CrossRef]
  185. Blache, C.A.; Manuel, E.R.; Kaltcheva, T.I.; Wong, A.N.; Ellenhorn, J.D.I.; Blazar, B.R.; Diamond, D.J. Data from Systemic Delivery of Salmonella Typhimurium Transformed with IDO ShRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. Cancer Res. 2012, 72, 6447–6456. [Google Scholar] [CrossRef]
  186. Phan, T.; Nguyen, V.H.; D’Alincourt, M.S.; Manuel, E.R.; Kaltcheva, T.; Tsai, W.; Blazar, B.R.; Diamond, D.J.; Melstrom, L.G. Salmonella-Mediated Therapy Targeting Indoleamine 2, 3-Dioxygenase 1 (IDO) Activates Innate Immunity and Mitigates Colorectal Cancer Growth. Cancer Gene Ther. 2020, 27, 235–245. [Google Scholar] [CrossRef]
  187. Sivasankar, C.; Hewawaduge, C.; Muthuramalingam, P.; Lee, J.H. Tumor-Targeted Delivery of Lnc Antisense RNA against RCAS1 by Live-Attenuated Tryptophan-Auxotrophic Salmonella Inhibited 4T1 Breast Tumors and Metastasis in Mice. Mol. Ther. Nucleic Acids 2023, 34, 102053. [Google Scholar] [CrossRef] [PubMed]
  188. Karpenko, L.I.; Danilenko, A.V.; Bazhan, S.I.; Danilenko, E.D.; Sysoeva, G.M.; Kaplina, O.N.; Volkova, O.Y.; Oreshkova, S.F.; Ilyichev, A.A. Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen. Microb. Biotechnol. 2012, 5, 241–250. [Google Scholar] [CrossRef] [PubMed]
  189. Chen, J.; Zhao, S.; Tan, W.; Wang, T.; Wu, S.; Wang, C.; Jiang, Y.; Zhou, T.; Zhang, Z.; Zhao, L. Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy. Sci. Rep. 2021, 11, 20083. [Google Scholar] [CrossRef]
  190. Yoon, W.; Park, Y.; Kim, S.; Bang, I.S. Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2. Vaccines 2022, 10, 67. [Google Scholar] [CrossRef] [PubMed]
  191. Prayoga, W. Concurrent emergencies: Overlapping Salmonella and COVID-19 concerns in public health strategies and preparedness. Front. Public Health 2024, 12, 1331052. [Google Scholar] [CrossRef] [PubMed]
  192. Kumar, V.; Yasmeen, N.; Pandey, A.; Ahmad Chaudhary, A.; Alawam, A.S.; Ahmad Rudayni, H.; Islam, A.; Lakhawat, S.S.; Sharma, P.K.; Shahid, M. Antibiotic Adjuvants: Synergistic Tool to Combat Multi-Drug Resistant Pathogens. Front. Cell. Infect. Microbiol. 2023, 13, 1293633. [Google Scholar] [CrossRef]
  193. Puyol McKenna, P.; Naughton, P.J.; Dooley, J.S.G.; Ternan, N.G.; Lemoine, P.; Banat, I.M. Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits. Pharmaceuticals 2024, 17, 138. [Google Scholar] [CrossRef]
  194. Sun, H.; Wan, Y.; Du, P.; Bai, L. The Epidemiology of Monophasic Salmonella Typhimurium. Foodborne Pathog. Dis. 2020, 17, 87–97. [Google Scholar] [CrossRef]
  195. D’Incau, M.; Salogni, C.; Giovannini, S.; Ruggeri, J.; Scali, F.; Tonni, M.; Formenti, N.; Guarneri, F.; Pasquali, P.; Alborali, G.L. Occurrence of Salmonella Typhimurium and Its Monophasic Variant (4, [5],12:I:-) In Healthy and Clinically Ill Pigs in Northern Italy. Porc. Health Manag. 2021, 7, 34. [Google Scholar] [CrossRef]
  196. Qin, X.; Xiao, L.; Li, J.; Yang, M.; Yang, C.; Dong, Q. Molecular Characterization and Antibiotic Resistance of Salmonella Enterica Serovar 1,4,[5],12:I:- Environmental Isolates from Poultry Farms. Food Qual. Saf. 2022, 6, fyac062. [Google Scholar] [CrossRef]
  197. Larkin, L.; Pardos de la Gandara, M.; Hoban, A.; Pulford, C.; Jourdan-Da Silva, N.; de Valk, H.; Browning, L.; Falkenhorst, G.; Simon, S.; Lachmann, R. Investigation of an International Outbreak of Multidrug-Resistant Monophasic Salmonella Typhimurium Associated with Chocolate Products, EU/EEA and United Kingdom, February to April. Eurosurveillance 2022, 2022, 27. [Google Scholar] [CrossRef]
Figure 1. Overview of aspects of Salmonella related to human health.
Figure 1. Overview of aspects of Salmonella related to human health.
Applmicrobiol 04 00104 g001
Figure 2. Possible AMR Pathways in Biofilm (A); Approaches to Gene Therapy (B).
Figure 2. Possible AMR Pathways in Biofilm (A); Approaches to Gene Therapy (B).
Applmicrobiol 04 00104 g002
Table 1. Examples of genes in NTS identified with a role in biofilm formation.
Table 1. Examples of genes in NTS identified with a role in biofilm formation.
Gene ResponsibleFunctionReference
flgK, rfbAFlagella, lipopolysaccharide production[72]
bcsABZC, bcsEFGSynthesis of exopolysaccharide cellulose[73]
EutE, Sufs/SufE, OmpL CopGBiosynthesis of aldehyde; dehydrogenase; cysteine desulfurase transporter protein; ribbon helix protein[74]
Cdg, trx, rtxDecrease in biofilm mass[75]
fadIRate of biofilm formation[75]
marTGeneral regulation of biofilm-related genes[76]
fimA, fimHAdherence-mediated biofilm formation[77]
bapABiofilm mass formation[78,79]
rspATemperature regulation of biofilm formation[80]
Table 2. Salmonella in approaches to cancer treatment.
Table 2. Salmonella in approaches to cancer treatment.
ApproachMethodReference
Delivery of oncolytic viruses (OVs)
Intracellular-delivering Salmonella to carry OVs into cancer cells[148]
Immune system regulating properties
Intracellular infection of melanoma[149]
Combination treatments
Deliver cytolysin to tumours[150,151]
Salmonella bioimaging to target metastatic tumours[146]
Genetically engineered Salmonella
Immune cytokines[147]
Anti-cancer drugs[152]
Expressing enzymes to activate anti-cancer pro-drugs[153]
Expressing tumour-specific antibodies[154]
Expressing oncogene silencing RNA[155]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Naughton, P.J.; Naughton, V.R.; Dooley, J.S.G. Salmonella: Role in Internal and External Environments and Potential as a Therapeutic Tool. Appl. Microbiol. 2024, 4, 1515-1533. https://doi.org/10.3390/applmicrobiol4040104

AMA Style

Naughton PJ, Naughton VR, Dooley JSG. Salmonella: Role in Internal and External Environments and Potential as a Therapeutic Tool. Applied Microbiology. 2024; 4(4):1515-1533. https://doi.org/10.3390/applmicrobiol4040104

Chicago/Turabian Style

Naughton, Patrick J., Violetta R. Naughton, and James S. G. Dooley. 2024. "Salmonella: Role in Internal and External Environments and Potential as a Therapeutic Tool" Applied Microbiology 4, no. 4: 1515-1533. https://doi.org/10.3390/applmicrobiol4040104

APA Style

Naughton, P. J., Naughton, V. R., & Dooley, J. S. G. (2024). Salmonella: Role in Internal and External Environments and Potential as a Therapeutic Tool. Applied Microbiology, 4(4), 1515-1533. https://doi.org/10.3390/applmicrobiol4040104

Article Metrics

Back to TopTop